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EDITORIAL
hy viral hepatitis?
"leaders may well ask this question upon realising that this
ssue of the SAMJ is entirely devoted to viral infections of
he liver. Indeed, some may be moved to discard it in the
Jelief that these infections are caused by esoteric viruses
vhich they need not know much about. For those tempted
o do so we would counter that almost every South African
,dult has evidence of previous exposure to the hepatitis A
'irus; roughly 60% have been infected with hepatitis Band
letween 1% and 10% are infectious carriers of this virus;
j,16 - 0,75% have evidence of hepatitis C infection and as
nany as 8 - 14% hepatitis E."s At this point a few diehards
nay argue that hepatitis is usually subclinical and that when
t occurs it belongs to the realms only of general
)ractitioners, paediatricians and physicians. Wrong again!
the hepatitis viruses are a major cause of morbidity and
1l0rtality. Apart from classic hepatitis, which may progress
o acute liver failure, they can cause cirrhosis, carcinoma of
he liver, glomerulonephritis, polyarteritis nodosa, peripheral
leuritis, cryoglobulinaemia and bone marrow aplasia.6They
lot infrequently occur" in pregnant women, where some, like
lepatitis E, may result in 20% mortality' and others like
1epatitis B may be transmitted from mother to child during
jelivery.6 They may be confused with surgical conditions and
apart from being an important cause of bleeding
oesophageal varices may pose a far greater threat to the
surgeon than HIV infection." Anaesthetists will attest to the
fact that such patients often require special care. The fact
that many of these viruses are transmitted as a result of
poor socio-economic conditions and the advent of vaccines
for hepatitis A and B have made these diseases of great
interest to community health physicians. lO•11 Those
responsible for the provision and funding of health care will
no doubt be interested in better ways of diagnosing or
preventing these conditions, the optimal frequency of often
expensive liver function and serological tests, and
cost/benefit analyses of various means of preventing these
diseases. Hepatic encephalopathy may bring these patients
to the attention of psychiatrists, while accompanying rashes
and the intractable itch of cholestasis may call for a
dermatologist. Finally, ethicists, workmen's compensation
commissioners and medicolegal buffs may have to
pronounce their verdicts concerning the transmission of
hepatitis from patient to health care provider and vice versa.
If we've left you out read no further!
The identification of the hepatitis B virus marked the
beginning of a new era in virology. From the apparently
humble observation that serum from an Australian Aborigine
contained an antigen which cross-reacted with serum from
persons who had required multiple infusions of blood
products and the profound insight which led to the,
hypothesis that this Australian antigen was related to a
hepatitis virus'2 flowed advances in immuno-electron
microscopy, molecular biology, immunology and
epidemiology which allowed the identification of hepatitis
viruses A to E. The results of these studies led to increased
knowledge of the clinical syndromes associated with each
virus, to relatively simple methods for their exact diagnosis,
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to advances in the therapy of chronic hepatitis" and finally
to vaccines for viruses B and A.
Readers may well next ask 'why viral hepatitis at this
time?'. As South Africa is being born to the world of
democracy, unique opportunities are becoming available as
this country's health system is transformed into one which
emphasises a primary health care approach." In particular
this policy framework is ideal for an immediate concerted
government-led programme for the control of hepatitis B
(and therefore hepatitis D as well) in the short term and
eradication of hepatitis B in the medium to long term. Such
a control programme, which is now possible, requires a
three-pronged approach:
1. A policy of universal childhood vaccination against
hepatitis B introduced by government. The political will to
ensure implementation of this policy is even more important
and the anticipated district-level service" may be well
placed to make hepatitis B widely accessible as part of a
basic package of primary health care services.
2. An information system is essential to manage a control
programme. Discussions are currently underway to create a
new health information system, including infectious disease
surveillance, in South Africa." The problems experienced in
hepatitis B data" need to be addressed, while both
laboratory and notification sources of data need to be
developed to serve control efforts and programme
management needs such as the identification of target areas
where vaccination coverage may need to be improved.
3. An ethos which promotes the notion of public health
and clinical medicine as parts of a continuum, where each
supports and strengthens the other, is essential. This ethos,
which is now gaining prominence with the participation of
medical schools in the development of schools of public
health,'6 is well illustrated in the context of hepatitis B
control, e.g. counselling of hepatitis B patients to use
condoms, introduction of single-use disposable syringes
and the importance of universal precautions for potentially
infectious body fluids. Building on this, control measures
targeted at household contacts and sexual partners
identified through patients presenting with clinical hepatitis
will become increasingly important as vaccine coverage
reduces childhood transmission. The value of these steps in
concomitantly preventing HIV infection is obvious.
We believe it is timeous to rekindle an interest in viral·
hepatitis lest the opportunity to control the principal viral
cause of liver disease passes us by. A childhood vaccination
programme together with a health information system to
support the implementation of this programme, with efforts
linking clinical care and public health measures as the
essential ingredients, are now becoming realities. This will
make control of hepatitis B a realisable objective.
This issue of the SAMJ contains articles on the clinical
and laboratory diagnosis of viral hepatitis, a review of each
of the viruses, the diagnosis and treatment of chronic
hepatitis, the relationship of hepatitis Band C to
hepatocellular carcinoma, the role of blood transfusion
services in limiting spread of these diseases by blood and
blood products, the medicolegal consequences of hepatitis,
and, perhaps most important for our proud new nation, an
article on prevention which holds the promise of eradication
not only of acute hepatitis but of many cases of chronic
disease including cirrhosis and hepatocellular carcinoma.
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ARTICLES
Clinical and biochemical
features of acute viral
hepatitis
C. W. Speannan
Viral hepatitis is a major cause of mortality and morbidity
worldwide. Acute viral hepatitis, although a generalised
systemic infection, presents with clinical manifestations
relating directly to inflammation of the liver with
hepatocellular dysfunction and jaundice.
MRC/UCT Liver Research Centre, Department of Medicine,
University of Cape Town
C. W. Spearman. M.B. CH.B.• M.MED.• F.C.P. (SA)
The most important causes of acute and chronic hepatitis
are the five hepatotrophic viruses, hepatitis A, B, C, D and E.
There are 2 other, as yet unidentified, hepatitis viruses, F
and G.
The clinical features of acute hepatitis caused by these
hepatotrophic viruses are similar and only minor features of
the clinical disease, together with the incubation period and
epidemiological history, help to distinguish the different acute
hepatitides. Specific diagnosis requires serological testing.
The clinical severity of acute hepatitis varies. Most
infections are asymptomatic, subclinical or anicteric with
mild gastro-intestinal symptoms only. Occasionally infection
results in acute fulminant hepatitis with an associated_ high
mortality.
Clinical features of acute viral
hepatitis
A full clinical history is important. Particular emphasis should
be paid to a recent history of travel, high-risk sexual
practices, blood transfusions and the use of drugs.
Symptoms
The most common symptoms experienced during the
prodromal phase include: malaise and fatigue, myalgia,
anorexia, nausea and vomiting, right upper quadrant
discomfort and fever.' Between 5% and 15% of patients
with hepatitis B may develop a serum-sickness-Iike
syndrome. Other extrahepatic manifestations, which may
occur in acute viral hepatitis, include urticaria and
angioneurotic oedema, arthritis, vasculitic and renal lesions,
myocarditis and cardiomyopathy, pancreatitis and CSF
abnormalities! The prodromal symptoms usually last a few
days to 2 weeks and are followed by the development of
jaundice. However, jaundice may occur in the absence of
any prodromal symptoms. Frequently, the systemic
symptoms improve with the development of jaundice.
Occasionally there is a prolonged cholestatic phase with
associated pruritus. If there are minimal prodromal
symptoms it is often difficult clinically to distinguish this form
of viral hepatitis from extrahepatic cholestasis or drug-
induced cholestasis.
During recovery, the nausea improves and the appetite
returns. General malaise may persist for some time and
relapses associated with an exacerbation of symptoms and
of jaundice occur in up to 5% of patients. These may be
precipitated by too early a· return to work or vigorous
exercise programmes.
Signs
The most common physical signs in acute hepatitis are
jaundice, right upper quadrant tenderness and mild
hepatomegaly. Splenomegaly occurs in 5 - 10% of patients
and lymphadenopathy is occasionally seen.' Skin rashes
may be present and in children with acute hepatitis B, a
papular acrodermatitis involving the arms, legs and face
may be found.
Fulminant viral hepatitis occurs in a small proportion of
patients. This is associated with the development of
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